tiprankstipranks
Trending News
More News >
SAGE Therapeutics, Inc. (US) (SAGE)
:SAGE
US Market
Advertisement

SAGE Therapeutics (SAGE) Price & Analysis

Compare
Followers

SAGE Stock Chart & Stats


SAGE Therapeutics News

SAGE FAQ

What was SAGE Therapeutics, Inc. (US)’s price range in the past 12 months?
Currently, no data Available
What is SAGE Therapeutics, Inc. (US)’s market cap?
Currently, no data Available
When is SAGE Therapeutics, Inc. (US)’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were SAGE Therapeutics, Inc. (US)’s earnings last quarter?
Currently, no data Available
Is SAGE Therapeutics, Inc. (US) overvalued?
According to Wall Street analysts SAGE Therapeutics, Inc. (US)’s price is currently Undervalued. Get more investment ideas with TipRanks Premium
    Does SAGE Therapeutics, Inc. (US) pay dividends?
    SAGE Therapeutics, Inc. (US) does not currently pay dividends.
    What is SAGE Therapeutics, Inc. (US)’s EPS estimate?
    SAGE Therapeutics, Inc. (US)’s EPS estimate for its next earnings report is not yet available.
    How many shares outstanding does SAGE Therapeutics, Inc. (US) have?
    Currently, no data Available
    What happened to SAGE Therapeutics, Inc. (US)’s price movement after its last earnings report?
    Currently, no data Available
    Which hedge fund is a major shareholder of SAGE Therapeutics, Inc. (US)?
    Currently, no hedge funds are holding shares in SAGE

    Company Description

    SAGE Therapeutics, Inc. (US)

    SAGE Therapeutics (SAGE) is a biopharmaceutical company committed to developing novel therapies for central nervous system (CNS) disorders. Founded in 2010 and headquartered in Cambridge, Massachusetts, SAGE focuses on identifying and developing medicines that target the brain's neurotransmitter pathways to address conditions such as depression, insomnia, and other CNS-related diseases. The company's flagship products include Zulresso (brexanolone) for the treatment of postpartum depression and other promising compounds in its pipeline aimed at various psychiatric and neurological conditions.

    SAGE Therapeutics (SAGE) Earnings & Revenues

    Currently, no data available
    Please return soon. This page is being updated.
    Similar Stocks
    Company
    Price & Change
    Follow
    Akebia Therapeutics
    Capricor Therapeutics
    Bicycle Therapeutics
    Opthea Limited Sponsored ADR
    Cullinan Management

    Ownership Overview

    17.74%82.25%
    Insiders
    17.74%
    Mutual Funds
    ― Other Institutional Investors
    82.25% Public Companies and
    Individual Investors

    Options Prices

    Currently, No data available
    ---
    Popular Stocks
    What am I Missing?
    Make informed decisions based on Top Analysts' activity
    Know what industry insiders are buying
    Get actionable alerts from top Wall Street Analysts
    Find out before anyone else which stock is going to shoot up
    Get powerful stock screeners & detailed portfolio analysis